GMAB
Genmab A/S
Price Chart
Latest Quote
$25.94
+0.33 (+1.29%)
Current Price
| Previous Close | $25.61 |
| Open | $25.96 |
| Day High | $26.18 |
| Day Low | $25.85 |
| Volume | 1,244,046 |
Stock Information
| Shares Outstanding | 613.94M |
| Total Debt | $5.35B |
| Cash Equivalents | $1.52B |
| Revenue | $3.90B |
| Net Income | $821.00M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $15.93B |
| P/E Ratio | 19.65 |
| EPS (TTM) | $1.32 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $19.75B |
| Sales | $3.90B |
| Income | $821.00M |
| Book/sh | $9.26 |
| Cash/sh | $2.48 |
| Employees | 3K |
Financial Ratios
| Quick Ratio | 2.17 |
| Current Ratio | 2.18 |
| Debt/Eq | 94.17 |
| EPS Growth TTM | -72.80% |
Returns & Margins
| ROA | 8.48% |
| ROE | 14.96% |
| Gross Margin | 93.31% |
| Operating Margin | 25.11% |
| Profit Margin | 21.05% |
Ownership
| Institutional Ownership | 13.57% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 14.17 |
| PEG | 1.71 |
| P/S | 4.08 |
| P/B | 2.80 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $36.82 |
Technical Indicators
| SMA20 | $25.31 |
| SMA50 | $26.42 |
| SMA200 | $29.26 |
| RSI | 68.76 |
| ATR | 0.6673 |
| Shares Float | 606.43M |
| Short Float | 1.66% |
| Short Ratio | 4.62 |
| Volatility | 0.68 |
| Rel Volume | 0.77 |
Performance History
| Week | +5.53% |
| Month | -4.10% |
| Quarter | +1.01% |
| 6 Months | -17.65% |
| YTD | -18.48% |
| Year | +22.59% |
| 3 Years | -33.06% |
| 5 Years | -41.07% |
| 10 Years | +56.45% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $25.94 | 1,261,300 |
| 2026-06-22 | $25.61 | 1,592,900 |
| 2026-06-18 | $25.27 | 1,809,900 |
| 2026-06-17 | $25.39 | 2,438,800 |
| 2026-06-16 | $24.74 | 2,191,700 |
| 2026-06-15 | $24.58 | 1,023,100 |
| 2026-06-12 | $25.08 | 1,113,700 |
| 2026-06-11 | $25.24 | 1,173,500 |
| 2026-06-10 | $24.49 | 876,200 |
| 2026-06-09 | $25.10 | 1,329,400 |
| 2026-06-08 | $24.80 | 1,435,900 |
| 2026-06-05 | $25.15 | 2,085,800 |
| 2026-06-04 | $24.73 | 1,240,300 |
| 2026-06-03 | $23.88 | 1,377,000 |
| 2026-06-02 | $23.85 | 3,617,100 |
| 2026-06-01 | $25.45 | 1,711,300 |
| 2026-05-29 | $26.33 | 2,199,600 |
| 2026-05-28 | $27.04 | 2,323,300 |
| 2026-05-27 | $26.71 | 790,700 |
| 2026-05-26 | $26.89 | 1,020,500 |
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
đ° Latest News
VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026
Exec Edge âĸ 2026-06-18T14:34:10Z
Genmabâs EPCORE Data Deepens Lymphoma Profile As Investors Weigh Upside
Simply Wall St. âĸ 2026-06-15T10:07:21Z
Truist Assigns Buy Rating to Genmab (GMAB)
Insider Monkey âĸ 2026-06-05T16:36:24Z
Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate
Simply Wall St. âĸ 2026-05-17T00:19:39Z
Morgan Stanley Maintains an âEqual Weightâ Rating on Genmab A/S (GMAB)
Insider Monkey âĸ 2026-05-13T17:53:55Z
Is It Time To Reassess Genmab (CPSE:GMAB) After Mixed MultiâYear Share Performance
Simply Wall St. âĸ 2026-05-08T12:17:13Z
Genmab A/S Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T20:58:37Z
DARZALEX royalties drive Genmabâs Q1 revenue higher amid expansion push
Investing.com âĸ 2026-05-07T18:46:35ZGenmab (GMAB) Rated Outperform on Oncology Pipeline
Insider Monkey âĸ 2026-05-02T17:51:47Z
Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook
Insider Monkey âĸ 2026-04-24T13:42:33Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $238,000,000 | $143,000,000 | $33,000,000 | $0 |
| Cost Of Revenue | $238,000,000 | $143,000,000 | $33,000,000 | $0 |
| Total Revenue | $3,720,000,000 | $3,121,000,000 | $2,390,000,000 | $2,087,681,170 |
| Operating Revenue | $3,667,000,000 | $2,977,000,000 | $2,266,000,000 | $1,969,947,754 |
| Expenses | ||||
| Interest Expense | $61,000,000 | $18,000,000 | $10,000,000 | $5,613,207 |
| Total Expenses | $2,470,000,000 | $2,106,000,000 | $1,618,000,000 | $1,185,682,005 |
| Other Income Expense | $-123,000,000 | $185,000,000 | $-87,000,000 | $56,563,854 |
| Net Non Operating Interest Income Expense | $77,000,000 | $126,000,000 | $132,000,000 | $41,019,589 |
| Interest Expense Non Operating | $61,000,000 | $18,000,000 | $10,000,000 | $5,613,207 |
| Operating Expense | $2,232,000,000 | $1,963,000,000 | $1,585,000,000 | $1,185,682,005 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $963,000,000 | $1,133,000,000 | $631,000,000 | $784,697,535 |
| Net Interest Income | $77,000,000 | $126,000,000 | $132,000,000 | $41,019,589 |
| Interest Income | $138,000,000 | $144,000,000 | $142,000,000 | $46,632,796 |
| Normalized Income | $1,061,400,000 | $975,010,000 | $698,193,390 | $740,293,484 |
| Net Income From Continuing And Discontinued Operation | $963,000,000 | $1,133,000,000 | $631,000,000 | $784,697,535 |
| Total Operating Income As Reported | $1,065,000,000 | $972,000,000 | $772,000,000 | $901,999,165 |
| Net Income Common Stockholders | $963,000,000 | $1,133,000,000 | $631,000,000 | $784,697,535 |
| Net Income | $963,000,000 | $1,133,000,000 | $631,000,000 | $784,697,535 |
| Net Income Including Noncontrolling Interests | $963,000,000 | $1,133,000,000 | $631,000,000 | $784,697,535 |
| Net Income Continuous Operations | $963,000,000 | $1,133,000,000 | $631,000,000 | $784,697,535 |
| Pretax Income | $1,204,000,000 | $1,326,000,000 | $817,000,000 | $999,582,608 |
| Special Income Charges | $-185,000,000 | $-43,000,000 | $0 | $0 |
| Interest Income Non Operating | $138,000,000 | $144,000,000 | $142,000,000 | $46,632,796 |
| Operating Income | $1,250,000,000 | $1,015,000,000 | $772,000,000 | $901,999,165 |
| Gross Profit | $3,482,000,000 | $2,978,000,000 | $2,357,000,000 | $2,087,681,170 |
| Per Share | ||||
| Diluted EPS | $1.54 | $1.69 | $0.96 | $1.20 |
| Basic EPS | $1.55 | $1.71 | $0.97 | $1.22 |
| Other | ||||
| Tax Effect Of Unusual Items | $-24,600,000 | $27,010,000 | $-19,806,610 | $12,159,803 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,459,000,000 | $1,219,000,000 | $957,000,000 | $1,000,734,035 |
| Total Unusual Items | $-123,000,000 | $185,000,000 | $-87,000,000 | $56,563,854 |
| Total Unusual Items Excluding Goodwill | $-123,000,000 | $185,000,000 | $-87,000,000 | $56,563,854 |
| Reconciled Depreciation | $71,000,000 | $60,000,000 | $43,000,000 | $52,102,074 |
| EBITDA (Bullshit earnings) | $1,336,000,000 | $1,404,000,000 | $870,000,000 | $1,057,297,889 |
| EBIT | $1,265,000,000 | $1,344,000,000 | $827,000,000 | $1,005,195,815 |
| Diluted Average Shares | $626,916,300 | $646,329,400 | $658,975,770 | $660,096,040 |
| Basic Average Shares | $621,510,850 | $641,866,470 | $653,097,440 | $657,831,300 |
| Diluted NI Availto Com Stockholders | $963,000,000 | $1,133,000,000 | $631,000,000 | $784,697,535 |
| Tax Provision | $241,000,000 | $193,000,000 | $186,000,000 | $214,885,073 |
| Restructuring And Mergern Acquisition | $185,000,000 | $43,000,000 | $0 | $0 |
| Gain On Sale Of Security | $62,000,000 | $228,000,000 | $-87,000,000 | $56,563,854 |
| Research And Development | $1,606,000,000 | $1,414,000,000 | $1,107,000,000 | $800,529,656 |
| Selling General And Administration | $626,000,000 | $549,000,000 | $478,000,000 | $385,152,348 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-3,631,000,000 | $3,054,000,000 | $4,672,000,000 | $3,905,640,553 |
| Total Assets | $12,873,000,000 | $6,414,000,000 | $5,232,000,000 | $4,334,978,914 |
| Total Non Current Assets | $9,988,000,000 | $2,514,000,000 | $320,000,000 | $273,607,853 |
| Non Current Deferred Assets | $171,000,000 | $127,000,000 | $31,000,000 | $36,269,952 |
| Non Current Deferred Taxes Assets | $171,000,000 | $127,000,000 | $31,000,000 | $36,269,952 |
| Non Current Accounts Receivable | $22,000,000 | $7,000,000 | $10,000,000 | $6,908,562 |
| Investmentin Financial Assets | $37,000,000 | $32,000,000 | $20,000,000 | $9,643,202 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $37,000,000 | $32,000,000 | $20,000,000 | - |
| Goodwill And Other Intangible Assets | $9,478,000,000 | $2,083,000,000 | $15,000,000 | $21,013,544 |
| Other Intangible Assets | $9,123,000,000 | $1,728,000,000 | $15,000,000 | $146,000,000 |
| Current Assets | $2,885,000,000 | $3,900,000,000 | $4,912,000,000 | $4,061,371,062 |
| Inventory | $18,000,000 | $9,000,000 | $8,000,000 | $0 |
| Receivables | $1,152,000,000 | $937,000,000 | $733,000,000 | $848,313,879 |
| Taxes Receivable | $40,000,000 | $14,000,000 | $0 | $26,194,965 |
| Accounts Receivable | $1,112,000,000 | $923,000,000 | $733,000,000 | $822,118,914 |
| Cash Cash Equivalents And Short Term Investments | $1,715,000,000 | $2,954,000,000 | $4,171,000,000 | $3,213,057,183 |
| Cash And Cash Equivalents | $1,715,000,000 | $1,380,000,000 | $2,204,000,000 | $1,423,883,476 |
| Debt | ||||
| Net Debt | $3,559,000,000 | - | - | - |
| Total Debt | $5,426,000,000 | $144,000,000 | $114,000,000 | $85,925,244 |
| Long Term Debt And Capital Lease Obligation | $5,135,000,000 | $131,000,000 | $101,000,000 | $75,274,543 |
| Long Term Debt | $5,001,000,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $291,000,000 | $13,000,000 | $13,000,000 | $10,650,700 |
| Current Debt | $273,000,000 | - | - | - |
| Other Current Borrowings | $273,000,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $7,026,000,000 | $1,277,000,000 | $545,000,000 | $408,324,818 |
| Total Non Current Liabilities Net Minority Interest | $5,599,000,000 | $533,000,000 | $177,000,000 | $145,943,379 |
| Tradeand Other Payables Non Current | $5,000,000 | $5,000,000 | $5,000,000 | $1,583,212 |
| Non Current Deferred Liabilities | $459,000,000 | $397,000,000 | $71,000,000 | $69,085,623 |
| Non Current Deferred Taxes Liabilities | $364,000,000 | $330,000,000 | $0 | - |
| Current Liabilities | $1,427,000,000 | $744,000,000 | $368,000,000 | $262,381,439 |
| Current Deferred Liabilities | $24,000,000 | $3,000,000 | $5,000,000 | $4,749,637 |
| Payables And Accrued Expenses | $1,112,000,000 | $728,000,000 | $350,000,000 | $246,981,102 |
| Payables | $1,112,000,000 | $728,000,000 | $350,000,000 | $246,981,102 |
| Other Payable | $1,069,000,000 | $489,000,000 | $342,000,000 | $246,981,102 |
| Total Tax Payable | $43,000,000 | $239,000,000 | $8,000,000 | $0 |
| Income Tax Payable | $43,000,000 | $239,000,000 | $8,000,000 | $0 |
| Accounts Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $5,847,000,000 | $5,137,000,000 | $4,687,000,000 | $3,926,654,097 |
| Total Equity Gross Minority Interest | $5,847,000,000 | $5,137,000,000 | $4,687,000,000 | $3,926,654,097 |
| Stockholders Equity | $5,847,000,000 | $5,137,000,000 | $4,687,000,000 | $3,926,654,097 |
| Gains Losses Not Affecting Retained Earnings | $-181,000,000 | $-226,000,000 | $-2,000,000 | $14,104,981 |
| Other Equity Adjustments | $-181,000,000 | $-226,000,000 | $-2,000,000 | $98,000,000 |
| Retained Earnings | $4,098,000,000 | $3,392,000,000 | $2,737,000,000 | $2,131,435,398 |
| Other | ||||
| Treasury Shares Number | $2,639,101 | $2,647,007 | $744,170 | $589,948 |
| Ordinary Shares Number | $61,599,307 | $63,540,179 | $65,330,365 | $65,371,625 |
| Share Issued | $64,238,408 | $66,187,186 | $66,074,535 | $65,961,573 |
| Tangible Book Value | $-3,631,000,000 | $3,054,000,000 | $4,672,000,000 | $3,905,640,553 |
| Invested Capital | $11,121,000,000 | $5,137,000,000 | $4,687,000,000 | $3,926,654,097 |
| Working Capital | $1,458,000,000 | $3,156,000,000 | $4,544,000,000 | $3,798,989,623 |
| Capital Lease Obligations | $152,000,000 | $144,000,000 | $114,000,000 | $85,925,244 |
| Total Capitalization | $10,848,000,000 | $5,137,000,000 | $4,687,000,000 | $3,926,654,097 |
| Additional Paid In Capital | $1,920,000,000 | $1,961,000,000 | $1,942,000,000 | $1,771,614,445 |
| Capital Stock | $10,000,000 | $10,000,000 | $10,000,000 | $9,499,273 |
| Common Stock | $10,000,000 | $10,000,000 | $10,000,000 | $9,499,273 |
| Non Current Deferred Revenue | $95,000,000 | $67,000,000 | $71,000,000 | $69,085,623 |
| Long Term Capital Lease Obligation | $134,000,000 | $131,000,000 | $101,000,000 | $75,274,543 |
| Current Deferred Revenue | $24,000,000 | $3,000,000 | $5,000,000 | $4,749,637 |
| Current Capital Lease Obligation | $18,000,000 | $13,000,000 | $13,000,000 | $10,650,700 |
| Investments And Advances | $37,000,000 | $32,000,000 | $20,000,000 | $19,142,475 |
| Goodwill | $355,000,000 | $355,000,000 | $0 | - |
| Net PPE | $280,000,000 | $265,000,000 | $244,000,000 | $190,273,320 |
| Accumulated Depreciation | $-157,000,000 | $-117,000,000 | $-100,000,000 | $-71,244,549 |
| Gross PPE | $437,000,000 | $382,000,000 | $344,000,000 | $261,517,869 |
| Leases | $132,000,000 | $101,000,000 | $101,000,000 | $59,298,493 |
| Construction In Progress | $3,000,000 | $14,000,000 | $6,000,000 | $33,535,313 |
| Other Properties | $127,000,000 | $128,000,000 | $102,000,000 | $75,274,543 |
| Machinery Furniture Equipment | $175,000,000 | $139,000,000 | $135,000,000 | $93,409,519 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-1,000,000 | $-3,000,000 | $-3,000,000 | $0 |
| Finished Goods | $13,000,000 | $11,000,000 | $9,000,000 | $0 |
| Work In Process | $0 | $0 | $0 | $0 |
| Raw Materials | $6,000,000 | $1,000,000 | $2,000,000 | $0 |
| Other Short Term Investments | $0 | $1,574,000,000 | $1,967,000,000 | $1,789,173,707 |
| Foreign Currency Translation Adjustments | - | $68,363,190 | $8,908,316 | $14,104,981 |
| Other Investments | - | - | $87,000,000 | $9,499,273 |
| Trading Securities | - | - | $47,000,000 | $9,643,202 |
| Buildings And Improvements | - | - | $686,000,000 | $523,000,000 |
| Available For Sale Securities | - | - | - | $67,000,000 |
| Long Term Provisions | - | - | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $1,131,000,000 | $1,082,000,000 | $1,017,000,000 | $517,422,531 |
| Operating Activities | ||||
| Operating Cash Flow | $1,186,000,000 | $1,126,000,000 | $1,071,000,000 | $563,047,827 |
| Cash Flow From Continuing Operating Activities | $1,186,000,000 | $1,126,000,000 | $1,071,000,000 | $563,047,827 |
| Operating Gains Losses | $-62,000,000 | $-228,000,000 | $87,000,000 | $-56,563,854 |
| Investing Activities | ||||
| Capital Expenditure | $-55,000,000 | $-44,000,000 | $-54,000,000 | $-45,625,297 |
| Investing Cash Flow | $-5,643,000,000 | $-1,447,000,000 | $-185,000,000 | $-397,386,261 |
| Cash Flow From Continuing Investing Activities | $-5,643,000,000 | $-1,447,000,000 | $-185,000,000 | $-397,386,261 |
| Net Other Investing Changes | $-7,215,000,000 | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-430,000,000 | $-560,000,000 | $-81,000,000 | $-130,686,970 |
| Issuance Of Capital Stock | $5,500,000,000 | $0 | $0 | - |
| Financing Cash Flow | $4,789,000,000 | $-566,000,000 | $-89,000,000 | $-113,559,493 |
| Cash Flow From Continuing Financing Activities | $4,789,000,000 | $-566,000,000 | $-89,000,000 | $-113,559,493 |
| Net Other Financing Charges | $-291,000,000 | $-16,000,000 | $-15,000,000 | $-12,665,698 |
| Net Common Stock Issuance | $5,070,000,000 | $-560,000,000 | $-81,000,000 | $-130,686,970 |
| Common Stock Issuance | $5,500,000,000 | $0 | $0 | - |
| Other | ||||
| Repayment Of Debt | $-13,000,000 | $-9,000,000 | $-14,000,000 | $-10,506,772 |
| End Cash Position | $1,715,000,000 | $1,380,000,000 | $2,204,000,000 | $1,423,883,476 |
| Beginning Cash Position | $1,380,000,000 | $2,204,000,000 | $1,419,000,000 | $1,289,166,511 |
| Effect Of Exchange Rate Changes | $3,000,000 | $63,000,000 | $-12,000,000 | $82,614,891 |
| Changes In Cash | $332,000,000 | $-887,000,000 | $797,000,000 | $52,102,074 |
| Proceeds From Stock Option Exercised | $23,000,000 | $19,000,000 | $21,000,000 | $40,299,947 |
| Common Stock Payments | $-430,000,000 | $-560,000,000 | $-81,000,000 | $-130,686,970 |
| Net Issuance Payments Of Debt | $-13,000,000 | $-9,000,000 | $-14,000,000 | $-10,506,772 |
| Net Long Term Debt Issuance | $-13,000,000 | $-9,000,000 | $-14,000,000 | $-10,506,772 |
| Long Term Debt Payments | $-13,000,000 | $-9,000,000 | $-14,000,000 | $-10,506,772 |
| Net Investment Purchase And Sale | $1,627,000,000 | $380,000,000 | $-131,000,000 | $-351,760,964 |
| Sale Of Investment | $2,622,000,000 | $1,636,000,000 | $1,451,000,000 | $1,044,056,477 |
| Purchase Of Investment | $-995,000,000 | $-1,256,000,000 | $-1,582,000,000 | $-1,395,817,441 |
| Net Business Purchase And Sale | $0 | $-1,783,000,000 | $0 | $0 |
| Purchase Of Business | $0 | $-1,783,000,000 | $0 | $0 |
| Net Intangibles Purchase And Sale | $-18,000,000 | $-17,000,000 | $-1,000,000 | $0 |
| Purchase Of Intangibles | $-18,000,000 | $-17,000,000 | $-1,000,000 | $0 |
| Net PPE Purchase And Sale | $-37,000,000 | $-27,000,000 | $-53,000,000 | $-45,625,297 |
| Purchase Of PPE | $-37,000,000 | $-27,000,000 | $-53,000,000 | $-45,625,297 |
| Taxes Refund Paid | $-460,000,000 | $-50,000,000 | $-155,000,000 | $-227,838,627 |
| Interest Received Cfo | $135,000,000 | $136,000,000 | $131,000,000 | $40,731,732 |
| Interest Paid Cfo | $-10,000,000 | $-5,000,000 | $-3,000,000 | $-2,302,854 |
| Change In Working Capital | $225,000,000 | $-109,000,000 | $198,000,000 | $-264,828,221 |
| Change In Payables And Accrued Expense | $400,000,000 | $122,000,000 | $90,000,000 | $40,731,732 |
| Change In Payable | $400,000,000 | $122,000,000 | $90,000,000 | $40,731,732 |
| Change In Inventory | $-9,000,000 | $-1,000,000 | $-8,000,000 | $0 |
| Change In Receivables | $-166,000,000 | $-230,000,000 | $116,000,000 | $-305,559,953 |
| Other Non Cash Items | $-77,000,000 | $-126,000,000 | $-132,000,000 | $-41,019,589 |
| Stock Based Compensation | $128,000,000 | $105,000,000 | $85,000,000 | $63,184,559 |
| Asset Impairment Charge | $32,000,000 | $17,000,000 | $0 | $0 |
| Depreciation Amortization Depletion | $71,000,000 | $60,000,000 | $43,000,000 | $52,102,074 |
| Depreciation And Amortization | $71,000,000 | $60,000,000 | $43,000,000 | $52,102,074 |
| Amortization Cash Flow | $16,000,000 | $11,000,000 | $3,000,000 | $20,149,973 |
| Amortization Of Intangibles | $16,000,000 | $11,000,000 | $3,000,000 | $20,149,973 |
| Depreciation | $55,000,000 | $49,000,000 | $40,000,000 | $31,952,101 |
| Gain Loss On Investment Securities | $-65,000,000 | $-136,000,000 | $21,000,000 | $94,704,875 |
| Net Foreign Currency Exchange Gain Loss | $3,000,000 | $-92,000,000 | $66,000,000 | $-151,268,729 |
| Net Income From Continuing Operations | $1,204,000,000 | $1,326,000,000 | $817,000,000 | $999,582,608 |
Fetched: 2026-06-23